Related Experiment Video
Updated: Jun 16, 2026

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Perioperative management in a patient with congenital factor VII deficiency following mechanical valve replacement: a
Xiaokang Luo1,2, Xue Yang3, Tucheng Sun1,2
1Department of Cardiovascular Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, No. 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China.
Background:
Congenital factor VII deficiency (CFVIID) is a rare hemorrhagic disorder which elevates perioperative bleeding risks. Mechanical prosthesis mandates lifelong anticoagulation, while international normalized ratio (INR) of CFVIID deviates significantly from the normal range which could not accurately reflect the real anticoagulation. Perioperative management for CFVIID patients undergoing mechanical valve replacement are highly challenging, with no clinical guidelines currently available.
Case Presentation:
We reported a 59-year-old CFVIID patient undergoing mechanical valve replacement. Perioperative recombinant activated factor VII (rFVIIa) replacement secured hemostasis. After postoperative cerebral thrombosis, anticoagulation of warfarin was initiated and guided by factor Ⅱ/Ⅹ activity (30-45%) rather than INR. No bleeding or recurrent thrombosis was observed.
Conclusions:
Perioperative rFVIIa replacement guarantees hemostatic safety for cardiac surgery. Lifelong warfarin anticoagulation is essential for CFVIID patient with mechanical prosthesis. Monitoring factor Ⅱ/Ⅹ activity instead of INR can balance bleeding and thrombosis risks for such cases.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Mitral Valve Prolapse III: Nursing Management
Mitral Stenosis IV: Nursing Management
Mitral Stenosis III: Medical Management
Aortic Regurgitation IV: Nursing Management
Mitral Regurgitation IV: Nursing Management
